Cover Image
Market Research Report

Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance

Published by GBI Research Product code 250520
Published Content info 69 Pages
Immediate Delivery Available
Price
Back to Top
Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
Published: September 11, 2012 Content info: 69 Pages
Description

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance". The report provides an overview of the most exciting innovations in drug delivery technologies in major therapeutic areas - oncology, vaccines, diabetes, rheumatology and respiratory diseases. Each chapter highlights emerging companies with technologies that have the potential to transform drug delivery in that specific therapeutic area. The report also explores the current environment in healthcare and the pharmaceutical industry, and examines drivers and challenges for the use of innovative drug delivery technologies.

Drug delivery technologies provide commercial opportunities for pharmaceutical companies by improving the chances of success for a drug development project. They enable the formulation of a promising molecule that might have poor solubility or require selective delivery to a particular tissue, such as the brain. Similarly, drug delivery technologies may enable companies to differentiate products within crowded therapeutic areas, facilitate life cycle management for existing drugs, and reposition existing drugs - proprietary or generic - in new indications where the needs of the patient population are different or, again, where more targeted delivery is required. Products that are reformulated with novel drug delivery systems do not meet the traditional criteria for innovative products - in other words, products that include new active moieties. Nevertheless, GBI Research's analysis shows that the commercial success of existing products that rely on innovative drug delivery technologies is clear, and these products make significant positive changes for patients.

Scope

  • Detailed analysis of the reasons for the industry to look closely at drug delivery technologies.
  • Exploration of the environment in healthcare and the pharmaceutical industry that is driving companies to invest in drug delivery.
  • Insight into collaborations between the largest pharmaceutical companies and smaller companies with innovative drug delivery technologies.
  • Detailed insight into innovation in drug delivery in key therapeutic areas: oncology, vaccines, diabetes, rheumatology and respiratory diseases.
  • Case studies of leading companies, their technologies and clinical data emerging from important drug development programs.

Reasons to buy

  • Identify leading drug delivery companies.
  • Learn about mergers, acquisitions and collaborations in drug delivery.
  • Develop strategies and priorities for investing in drug delivery technologies.
  • Understand the most important technologies and companies involved in developing new drug delivery technologies in key therapeutic areas.
  • Explore the needs of patients in each therapeutic area and the ways in which drug delivery technologies can be used to meet these within drug development pipelines.

Executive Summary

Patient's Come First, as Pharma Companies Try to Please with Innovation in Drug Delivery

Drug delivery can utilize various routes, with medication most commonly being administered orally or intravenously. Other routes include topical delivery, through the skin, or transmucosal delivery through the vagina, rectum, eye, nose, cheek, or under the tongue. In their latest report*, pharmaceutical industry experts GBI Research examines innovative drug delivery methods.

Sophisticated drug delivery systems can cater for patient requirements, or those of the molecule itself. Certain drug delivery systems can promote patient adherence with medication schedules, potentially improving efficacy outcomes and making products more cost effective, thereby providing commercial opportunities for pharmaceutical companies. Drug delivery methods can enable the use of promising molecules which have poor solubility, or require selective delivery to a particular tissue, such as the brain. Drug delivery technologies can enable companies to differentiate their products within crowded therapeutic areas, or improve upon existing drugs. The commercial success of innovative drug delivery technologies is clear, and the driving market competition creates significant positive changes for many patients.

Research is being directed toward drug delivery methods used for oncology treatments, as drug companies study new ways to deliver existing molecules. Reducing drug toxicity in cancer treatment would be a huge medical breakthrough, and may be achieved by reformulating products to remove toxic elements, or by closely targeting drugs to cancer cells to reduce peripheral damage.

A war against needles is also being fought, as diabetes patients hold out hope for new delivery technologies, while current insulin treatments all relying on subcutaneous methods, whether by injection, pen injectors, or insulin pumps. Similarly, specialists are looking at how vaccines may be delivered to mucosal systems rather than intravenously, as these could offer a painless and less invasive alternative to childhood injections.

Failure to understand patient needs can ultimately cause the commercial failure of a product, and drug delivery researchers will therefore benefit from contact with patients, identifying their most pressing needs and developing products around these. However, proof will be needed to back up claims that drug delivery methods are not a waste of valuable R&D funding. For instance, the link between convenience and adherence with medication schedules will come under closer scrutiny in the future, as reimbursement companies will demand clinical data to support the superiority of less frequent dosing regimens.

The global drug delivery market was estimated to be worth $101 billion in 2009, and set to rise to $199 billion in 2016 at a Compound Annual Growth Rate (CAGR) of 10.32%. Individual blockbuster products may earn over $1 billion as a single product.

Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance

This report provides an overview of the most exciting innovations in drug delivery technologies in major therapeutic areas - oncology, vaccines, diabetes, rheumatology and respiratory diseases.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Drug Delivery - An Overview

  • 2.1. Introduction
  • 2.2. The Drug Delivery Market
  • 2.3. Market Trends Affecting Drug Delivery
    • 2.3.1. Drivers within the Healthcare Environment
    • 2.3.2. Pharmaceutical Industry
  • 2.4. Leading Drug Delivery Companies
    • 2.4.1. Pharmaceutical Company Drug Delivery Portfolios
    • 2.4.2. Deal Making

3. Oncology

  • 3.1. Introduction
  • 3.2. PEGylation
  • 3.3. Protein-Based Drug Delivery Systems
    • 3.3.1. Albumin
    • 3.3.2. Other Fusion Proteins
    • 3.3.3. Hyaluronidase
  • 3.4. Nanoparticles for Drug Delivery
    • 3.4.1. Liposomes
    • 3.4.2. Dendrimers
    • 3.4.3. Polymer Delivery Systems
  • 3.5. Tumor Targeting
    • 3.5.1. Antibody-Drug Conjugates
  • 3.6. Conclusions

4. Vaccines

  • 4.1. DNA Vaccines
    • 4.1.1. DNA Vaccines Delivered in Viral Vectors
    • 4.1.2. Bacterial and Yeast-Based Antigen Delivery
  • 4.2. 'Naked' and Complexed DNA Vaccine Delivery
  • 4.3. Vaccine Delivery to the Mucosal System and Skin
  • 4.4. Intranasal Vaccine Delivery
  • 4.5. Oral Vaccine Delivery
  • 4.6. Transdermal Vaccine Delivery
    • 4.6.1. Intercell
    • 4.6.2. Microneedles for Intradermal Delivery
  • 4.7. Conclusions

5. Diabetes

  • 5.1. Introduction
  • 5.2. Innovation in Insulin Delivery
    • 5.2.1. Inhaled Insulin
    • 5.2.2. Oral Insulin
    • 5.2.3. Buccal Insulin
    • 5.2.4. Transdermal Insulin
  • 5.3. Next Generation Insulin Delivery Devices
    • 5.3.1. Pens
    • 5.3.2. Pumps
  • 5.4. GLP-1 Analogues
  • 5.5. Conclusions

6. Rheumatology

  • 6.1. Introduction
  • 6.2. Prefilled Syringes
  • 6.3. Autoinjectors
    • 6.3.1. New Materials in Autoinjector Design
  • 6.4. Alternatives to Autoinjectors
    • 6.4.1. Jet Injectors
    • 6.4.2. Other Needle-Free Devices
    • 6.4.3. Novel Injectors
  • 6.5. Conclusions

7. Respiratory Diseases

  • 7.1. Introduction
  • 7.2. Drug Delivery Devices
    • 7.2.1. Pressurized Metered Dose Inhalers
    • 7.2.2. Dry Powder Inhalers
    • 7.2.3. Aerosol Delivery Methods
    • 7.2.4. Advances in Particle Engineering
    • 7.2.5. Introduction of Electronics
  • 7.3. Innovation in Drug Carriers for Pulmonary Drug Delivery
  • 7.4. Alternative Routes of Delivery
  • 7.5. Conclusions

8. Outlook

9. Appendix

  • 9.1. Abbreviations
  • 9.2. References
  • 9.3. Methodology
    • 9.3.1. Primary Research
    • 9.3.2. Secondary Research
  • 9.4. Contact Us
  • 9.5. Disclaimer

List of Tables

  • Table 1: Innovation in Drug Delivery, Blockbuster Products Including Drug Delivery Systems, 2012
  • Table 2: Innovation in Drug Delivery, Examples of Leading Drug Delivery Companies, 2012
  • Table 3: Innovation in Drug Delivery, Examples of Licensing Deals for Drug Delivery, 2012
  • Table 4: Innovation in Drug Delivery, Examples of Licensing Deals for Drug Delivery, 2012
  • Table 5: Innovation in Drug Delivery, Examples of Oncology Drugs in Clinical Development with Drug Delivery Systems (by Technology Platform), 2012
  • Table 6: Innovation in Drug Delivery, Advances in PEGylation Technologies, 2012
  • Table 7: Innovation in Drug Delivery, Examples of Nanoparticulate Drug Delivery Systems, 2012
  • Table 8: Innovation in Drug Delivery, Approved Cancer Drugs with Liposomal Delivery Systems, 2012
  • Table 9: Innovation in Drug Delivery, Companies Developing Viral Vector Delivery Systems for Vaccines, 2012
  • Table 10: Innovation in Drug Delivery, Companies Developing Intranasal Vaccines and their Technologies, 2012
  • Table 11: Innovation in Drug Delivery, Companies Developing Oral Vaccines and their Technologies, 2012
  • Table 12: Innovation in Drug Delivery, Companies Developing Transdermal Vaccines and their Technologies, 2012
  • Table 13: Innovation in Drug Delivery, Inhaled Insulin Products and their Development Status, 2012
  • Table 14: Innovation in Drug Delivery, Oral Insulin Products and their Development Status, 2012
  • Table 15: Innovation in Drug Delivery, GLP-1 Analogs and their Development Status, 2012
  • Table 16: Innovation in Drug Delivery, Leading Drugs for Arthritis and their Delivery Systems, 2012
  • Table 17: Innovation in Drug Delivery, Leading Autoinjector Manufacturers and their Products, 2012
  • Table 18: Innovation in Drug Delivery, Examples of Liquid Jet Injectors for Needle Free Delivery, 2012
  • Table 19: Innovation in Drug Delivery, Companies Commercializing Aerosol Drug Delivery Technologies, 2012
  • Table 20: Innovation in Drug Delivery, Drug Delivery Requirements in Different Therapeutic Areas, 2012

List of Figures

  • Figure 1: Innovation in Drug Delivery, Commonly Used Options for Drug Delivery, 2012
  • Figure 2: Innovation in Drug Delivery, Uses of Drug Delivery Technology, 2012
  • Figure 3: Innovation in Drug Delivery, Commercial Opportunities for Drug Delivery Systems, 2012
  • Figure 4: Innovation in Drug Delivery, Reducing Drug Toxicity Through Drug Delivery, 2012
Back to Top